z-logo
open-access-imgOpen Access
Treatment of Melasma with Potent Topical Corticosteroids
Author(s) -
Amrinder J. Kanwar,
Sandipan Dhar,
Sukhjeet Kaur
Publication year - 1994
Publication title -
dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.224
H-Index - 92
eISSN - 1421-9832
pISSN - 1018-8665
DOI - 10.1159/000247129
Subject(s) - melasma , dermatology , medicine , corticosteroid , adrenal cortex hormones , surgery
A.J. Kanwar, MD, Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012 (India) Melasma in a pattern of acquired hyper-melanosis seen mostly in women of child-bearing age and occasionally in males occurring on sun-exposed areas. It is often considered either as a physiological change in pregnancy, or oral contraceptives are incriminated. The condition may fade after delivery but is often persistent [1]. Distribution-wise, the lesions are centrofacial (63%), malar (21%) and mandibular (16%) [2]. On Wood’s lamp examination, melasma is classified as epidermal, dermal and compound (epidermal and dermal). Histopathologically, the pigmentation is either epidermal or dermal. This differentiation has clinical significance as epidermal pigmentation responds better to therapy whereas dermal pigmentation is usually resistant to all forms of treatment. Kligman and Willis [3] reported good response with a combination of 0.1% tretinoin, 5% hydro-quinone and 0.1% dexamethasone, but depigmentation was not attainable when any of the components was omitted; however, a double-blind study with 2% hydroquinone and 1% retinoic acid without any corticoste-roid produced an equally good response [2]. We recently treated 10 patients with melasma (7 females and 3 males) with a potent topical corticosteroid, i.e. clobetasol propionate (0.05%). The ages of the patients ranged from 20 to 40 years, and the duration of melasma was from 3 to 14 months. Of 10, 5 had centrofacial, 4 malar and 1 mandibular patterns of distribution. None of the female patients were pregnant or on oral contraceptives at the time of examination or in the preceding 6 months. Patients were instructed to apply clobetasol propionate (0.05%) cream topically initially twice daily for 4 weeks followed by once daily for another 4 weeks. In all patients fading of pigmentation was observed after 2 weeks, and it was more discernible after 4-6 weeks. Eighty to ninety percent clearance of pigmentation was observed after 6-8 weeks in 7 patients; in 3 therapy had to be stopped after 4 weeks because of local atrophy and telangiectasiae. In addition to the topical corticosteroid, patients were advised to use a sun screen. In 4 of 7 patients in whom the pigmentation had cleared, it reappeared at the same sites after about 2-3 weeks after stopping the treatment and gradually progressed to pretreatment state during the next 4–6 months of follow-up. Though Wood’s light and histopatholog-ical examination were not done to categorize the therapeutic response, initial clearance of pigmentation with clobetasol propionate was encouraging though the success was shortlived. Kligman and Willis [3], however, failed to find any beneficial effect of only topical

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom